Skip to main content
. 2015 Jan;6(1-2):9–18. doi: 10.18632/genesandcancer.48

Figure 5. Pharmacological inhibition of cells harboring mutant BRAF.

Figure 5

A: MEK Inhibition with PD0325901 at 0 μM, 0.1 μM, and 1.0 μM for one hour in RPMI 2% FBS of Ink4a/Arf-deficient astrocytes infected with BRAF-KD (KD) and BRAFV600E (FLVE) with corresponding uninfected, negative control astrocytes. MEK inhibition decreases P-Erk levels by western blot. B: Growth inhibition in Ink4a/Arf-deficient astrocytes infected with BRAF-KD (KD) and BRAFV600E (FLVE) treated in triplicate with 1 μmol/l PD0325901 (901), 1 μmol/l NVP-BEZ235 (BEZ) or combination (BEZ/901) for 96 h. Cells treated with vehicle alone (DMSO) served as controls. Cell growth was measured using the ATPlite assay. Data was normalized to untreated controls and are represented as mean ± S.E.M. C: Apoptosis induced by inhibition of MEK and PI3K/mTOR signaling in mouse astrocytes. Ink4a/Arf-deficient astrocytes infected with BRAF-KD (KD) and BRAFV600E (FLVE) were treated in triplicate with either DMSO as a control, 1 μmol/l PD0325901 (901), 1 μmol/l NVP-BEZ235 (BEZ) or in combination (BEZ/901) for 96 h. Apoptosis was quantitated using Guava ViaCount. Data are represented as mean ± S.E.M.